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Abstract
Background:  Despite the well-documented benefits of using warfarin to prevent stroke,
physicians remain reluctant to initiate therapy, and especially so with the elderly owing to the higher
risk of hemorrhage. Prior research suggests that patients are more accepting of the risk of bleeding
than are physicians, although there have been few qualitative studies. The aim of this study was to
employ qualitative methods to investigate the experience and perspective of individuals taking
warfarin.
Methods: We conducted face-to-face interviews with 21 older patients (12 male, 9 female) who
had been taking warfarin for a minimum of six months. Participants were patients at a family
practice clinic situated in a large, tertiary care teaching hospital. We used a semistructured
interview guide with four main thematic areas: decision-making, knowledge/education, impact, and
satisfaction. Data were analysed according to the principles of content analysis.
Results and Discussion: Participants tended to have minimal input into the decision to initiate
warfarin therapy, instead relying in great part on physicians' expertise. There appeared to be low
retention of information received regarding the therapy; half the patients in our sample possessed
only a superficial level of understanding of the risks and benefits. This notwithstanding, participants
reported a high level of satisfaction with the care provided and a low level of impact on their day-
to-day lives.
Conclusions: Minimal patient involvement in the initial decision and modest knowledge did not
appear to diminish satisfaction with warfarin management. At the same time, care providers exert
a tremendous influence on the initiation of warfarin therapy and should strive to incorporate
patient preferences and expectations into the decision-making process.
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Background
Warfarin therapy is an effective anticoagulant indicated
for the prophylaxis and/or treatment of venous thrombo-
sis and atrial fibrillation (AF), the most common cardiac
arrhythmia in older individuals [1]. Oral anticoagulation
with warfarin is known to reduce the risk of disabling
stroke; indeed, the benefits of oral anticoagulation have
been demonstrated in a number of systematic reviews,
providing high evidential support for prophylaxis [2,3].
Published guidelines on the management of AF empha-
size the importance of warfarin therapy for the prevention
of stroke [4]. Likewise, there is convincing evidence that
long-term warfarin therapy is a highly effective method of
preventing recurrent venous thromboembolism [5].
Despite the strong evidence base and the endorsement of
warfarin therapy by authoritative guidelines, current pre-
scribing patterns of warfarin remain something of a puz-
zle. Bungard and associates have described the 'real world'
use of warfarin therapy as "sub-optimal" [6] and have esti-
mated that only 15% to 44% of patients eligible for anti-
coagulation are actually prescribed warfarin [7]. Hart
concurs that the use of warfarin is poor, noting that "it is
often given to patients who benefit minimally, while
those patients who would benefit most are not treated"
[8].
Bungard and his colleagues recently conducted a system-
atic review of the reasons for the underuse of warfarin,
identifying patient, provider, and system factors as well as
identifying limitations in research studies and arguing for
further research into these factors [6]. Studies employing
trade-off methods to determine the risk/benefits thresh-
old where therapy becomes acceptable have demon-
strated that patients are more willing to assume risk when
better informed about the medication [9]. Physicians,
however, are reluctant to prescribe warfarin to elderly
patients owing to concerns regarding compliance, a per-
ceived risk of falls, and the lack of randomized controlled
trial evidence in this patient population [7]. A recent study
reporting the findings of interviews with individuals with
a history of AF indicated that patients' health beliefs and
attitudes toward death play an important role in their
decision-making [10].
Clearly, the decision to initiate warfarin therapy is a com-
plex interaction of many variables, involving patient, pro-
vider, and system factors. Most studies examining
anticoagulation practices in primary care have used sur-
veys or other forms of quantitative methods; however,
given the inherent complexity of this subject matter, it is
likely that qualitative research methods could provide sig-
nificant additional insight. A comprehensive literature
search failed to find a qualitative investigation of patient
perspectives and experiences taking warfarin. The aim of
this study, therefore, was to employ qualitative methods
to examine the experience and perspective of individuals
on long-term warfarin therapy for atrial fibrillation as a
means to assess the extent to which the physician-identi-
fied barriers reported by Bungard [6] are in concordance
with the unique views of patients.
Methods
Participants and setting
This research was undertaken in a family practice clinic sit-
uated in a large, tertiary care teaching hospital. The clinic
employs 12 physician full-time equivalents working in
three teams; each four-physician team is supported by two
registered nurses. The practice, which serves a medium-
high socioeconomic status population, has a large propor-
tion of elderly patients and the prevalence of AF is higher
than reported elsewhere [1]. The prevalence of atrial fibril-
lation in our population as a whole is 3.9 percent. When
considering different age groups, the prevalence rises as
high as 18.2 percent and 18.5 percent for patients aged
80–89 and 90–99 years, respectively. A recent chart audit
study found that the majority of eligible AF patients in the
clinic (78%) are being treated with warfarin for stroke pre-
vention [11]. Comprehensive anticoagulation services are
provided and the clinic offers access to physicians on-call
24 hours a day. The nurses maintain an historical record
of International Normalized Ratio (INR) results and war-
farin dosage changes for each individual patient and, in
consultation with the physicians, inform patients of pre-
scribed warfarin dosage changes in a timely fashion, usu-
ally on the same day as the INR reading.
Potential participants were identified by the clinic nursing
staff. The inclusion criteria stated that the patient must
currently be on warfarin therapy and have been so for a
minimum period of six consecutive months. Patients were
excluded from the study if a significant co-morbidity pre-
vented their participation, if they were unable to converse
in English, or if they were unwilling/unable to provide
informed consent. From a pool of approximately 60 eligi-
ble candidates, the nurses purposively sampled in order to
achieve an even gender split as well as an equivalent
number of patients who were both normally in-range and
out-of-range on their INR tests. A total of 24 patients were
invited to participate in the study. Three patients declined
to take part, two of whom expected to be unavailable dur-
ing the interview phase, whereas the third declined due to
lack of interest. All participants signed informed consent
forms in advance of their participation in the study, which
was approved by the Research Ethics Board of the host
institution. A demographic profile of the sample is pre-
sented in Table 1. The mean age of participants was 74
years; there were 12 males, 9 females. The majority were
both married (86%) and retired (86%). The mean lengthBMC Family Practice 2004, 5:15 http://www.biomedcentral.com/1471-2296/5/15
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of time participants had been on warfarin therapy was 4.6
years (range = 1 year to 10 years).
Data collection and analysis
We utilized a semi-structured interview guide that was
developed on the basis of salient issues identified in the
scientific literature, specifically the various barriers to the
prescription of warfarin for atrial fibrillation as reported
by Bungard et al [6]. Interviewees were asked to share their
experiences with warfarin in relation to four specific con-
tent areas or themes: decision-making, knowledge and
education, impact on daily life, and patient satisfaction.
Throughout the course of the interview, participants were
provided several opportunities to raise issues or to
describe experiences that had not been specifically
addressed. Standard demographic information was also
collected. Three of the authors (GCD, JM, and BT) shared
the task of conducting the interviews. The protocol for
assignment of each individual participant to an interview-
ing author ensured that there had been no previous clini-
cal contact between the two parties; moreover,
interviewers were blind to interviewees' INR status. The
interviews lasted an average of 45 minutes and took place
either in the clinic (n = 13) or in participants' homes (n =
8), in accordance with each participant's preference. Data
collection ceased when, in the consensus of the research
team, saturation had been reached; that is, no new ideas
or perspectives were emerging. All interviews were audio-
taped and transcribed verbatim.
Given the pre-determined nature of the themes, as
described above, we employed a content analysis
approach to the analysis of the interview data. Whereas
grounded theory is used to develop data-induced themes
or hypotheses, content analysis is the better-suited
approach in those instances where the codes, categories,
or themes of interest to the investigators have been previ-
ously discovered and described [12], as is the case in the
present study.
Precise criteria were developed for each of the four pre-
determined themes in the codebook, namely decision-
making, knowledge/education, impact on daily life, and
patient satisfaction. The 21 transcripts were then coded
according to these criteria. Each transcript was coded by at
least two members of the research team using a standard-
ized coding form. Tests for inter-coder reliability indicated
a high level of agreement among the coders; instances of
disagreement were resolved through a process of discus-
sion and negotiation that included both the fourth author
and the principal investigator (CST & REGU). This process
yielded a unit-by-variable matrix that allowed for substan-
tive analysis of the data. In order to strengthen the validity
of the findings, the analytic processes of coding and
Table 1: Demographic profile of participants
Code Age (years) Sex Marital Status Employment 
Status
Years on 
Warfarin
INR in Range?
P1 67 F Widowed Retired 5 Yes
P2 73 M Married Retired 10 Yes
P3 84 M Widowed Retired 5 Yes
P4 83 F Married Retired 4 No
P5 81 F Married Retired 1 Yes
P6 76 F Married Retired 3 Yes
P7 75 M Divorced Retired 2 No
P8 60 M Married Working 3 No
P9 79 F Married Retired 5 No
P10 67 F Married Retired 2 No
P11 76 M Married Retired 5 No
P12 80 M Married Retired 2 No
P13 53 M Married Working 8 No
P14 71 M Married Retired 3 Yes
P15 69 M Married Retired 4 Yes
P16 77 F Married Retired 5 Yes
P17 78 M Married Retired 1 No
P18 80 M Married Retired 10 Yes
P19 71 M Married Working 7 No
P20 71 F Married Retired 6 No
P21 82 F Married Retired 5 YesBMC Family Practice 2004, 5:15 http://www.biomedcentral.com/1471-2296/5/15
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interpretation were reviewed by an independent external
reader (DG).
Results
Decision-making
The great majority of participants reported that the deci-
sion to initiate warfarin therapy had been made by "the
doctor" – a term that was used to refer not only to family
physicians and general practitioners, but also to specialists
and attending physicians in urgent care settings. Typically,
there was little or no patient involvement in the decision-
making process (Table 2A). In most cases, this unilateral
decision-making appeared to be related to the high level
of trust that patients place in the medical expertise of phy-
sicians; indeed, the phrase "doctor knows best" was com-
monly-used in these accounts (Table 2B). For a smaller
number of participants, the specific circumstances sur-
rounding the initial decision to commence therapy served
to preclude any degree of significant involvement on their
part (Table 2C).
Knowledge and education
The level of knowledge and understanding of the benefits
and risks associated with warfarin therapy tended to vary
with age. Elderly patients (aged 75+) demonstrated
poorer knowledge than their younger counterparts;
indeed, the knowledge level among older participants
appeared to be quite superficial and scattered (Table 3A).
Whereas elderly patients could not explain with any
degree of exactitude the rationale for taking warfarin and
the associated risks, for a subset of participants, most of
whom were less than 75 years old, the knowledge level
was higher and, for a small number, considerably higher
(Table 3B). Overall, less than half of our sample was able
to name one specific benefit, risk, and lifestyle change/
concern associated with warfarin therapy.
According to participants' accounts, educational efforts
aimed at informing patients about warfarin were minimal
and insufficient (Table 3C). Those who were able to recall
some form of education typically referred to a "booklet"
or "sheet" supplied by either the clinic or a pharmacy. In
several cases, spouses were more knowledgeable than
patients and appeared to play an important role in moni-
Table 2: Quotations: Decision-making
A. Minimal patient involvement
My decision [to take warfarin]? It was the doctor's decision. (P5)
I had nothing to say [regarding decision to initiate warfarin]. If the doctor tells me something, I do it. (P17)
Q: What influenced your decision to take the drug?
A: Well, because I was told to.
Q: The main reason is that it was the physician's recommendation?
A: Yes. (P20)
I don't recall him [the physician] saying anything much. He said a lot of things when he examined me first, and he put me up in the ward overnight, 
then he started with the medications. That's all there was to it...Not really, no [no much discussion on reasons to start warfarin]. He just said that, 
"This is what medication we're going to put you on for the myopathy." That was it. (P11)
B. Trust of physicians
I just figured the doctor knows best... (P1)
A: No [trouble to decide to take warfarin], because I knew nothing about it. My doctor, as far as I know, is very competent so...
Q: So you are taking it basically because the doctor told you to?
A: That's right. (P6)
I'm at this hospital and it's got a very good reputation... Doctor knows best, I guess. They know exactly what you have to do for it, and they did it. 
(P14)
I can recall that I had no objection. I said, "You are the experts, you are the doctors. If I get any help, I mostly will appreciate it.".... I don't think I would 
trust myself that much [to make the right decision]. (P15)
C. Constraining effect of circumstances
When I went into the [clinic] to see my doctor, they admitted me to the cardiac emergency, and they kept me there all day ... I was in for just about 
a week. ... and when I was discharged the doctors explained that they were putting me on to certain medications, and Coumadin was one of them. 
(P10)
I had congestive heart failure, that's what I was in hospital for. I don't know what I was on when I was in hospital, but when I came out I had a whole 
slew of medications and Coumadin was one of them. (P5)
I had lymphoma, and then I had a bone marrow transplant for lymphoma, and I had my spleen taken out, and I started getting deep vein thrombosis. 
Then I had a pulmonary embolism at one point and they started me on it [warfarin] then... I had just about every complication in the book, and this 
[thrombosis] was one of them. I think it was around that time, or within a year after the thromboses started, they gave me warfarin. (P13)
The surgeon said I had to take it, basically. I don't like taking pills, so when I went in to get my one valve replaced, they gave me – they persuaded 
me – and I agreed to trying out something new that had just been approved. The reason for doing that was that I would not have to take 
Coumadin... Unfortunately, however, one of my other valves blew when I was in there [during surgery], so I got two for the price of one, and then 
there was no question I had to go on a blood thinner. (P19)BMC Family Practice 2004, 5:15 http://www.biomedcentral.com/1471-2296/5/15
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toring the regime. A number of participants lauded the
availability of clinic staff to answer questions; however,
two others reported the use of "scare tactics" by health
care professionals with regard to the need to take warfarin.
Impact of warfarin regime
While there is tremendous range in the perceived impact
of warfarin therapy on the lives of these patients, the vast
majority reported that they have not experienced compli-
cations (e.g., hemorrhage, drug interactions). Typically,
the decision to start taking warfarin did not precipitate sig-
nificant changes in their day-to-day lives; many partici-
pants reported experiencing only minor inconveniences
(Table 4A). For these individuals, warfarin is just another
pill to be taken everyday; many reported the use of some
reminder strategy, such as calendars, dosettes (pill boxes),
or taking the pill right before some regular activity, in
order to avoid missing a dose. On the other hand, a size-
able proportion (25%) of interviewees reported that
adhering to the warfarin regime does impact upon their
day-to-day lives. From the perspective of these patients,
who were more likely to have multiple co-morbid ill-
nesses and/or were taking multiple medications, the war-
farin regime presents a considerable struggle to be
managed, particularly when dosages needed to be
adjusted. Regular visits to the clinic, restrictions on diet
and alcohol intake, and anxiety regarding bleeding and
potential drug interactions counted among the most com-
Table 3: Quotations: Knowledge and education
A. Superficial level of knowledge
I don't really know what these different pills do for me. (P3)
I'm assuming these people know what they're doing. They're not doing this for nothing. They must have good reasons, and they tell me, "Hang on 
there, you're doing all right. Keep it up." So I do. I don't question them. Very little, if any. I probably wouldn't know what they were talking about if they 
started to explain it all, and what's the point of that? (P12)
Q: What do you think Coumadin is doing for you and your health?
A: It makes the blood sticky, I believe, or thins it. I really don't know.
Q: Do you know why they added the Coumadin?
A: No idea.
Q: It doesn't much matter to you?
A: It doesn't matter to me.
Q: Everyone's different. Some people like to know all the details.
A: Oh, I couldn't care less, just as long as it keeps me alive. (P17)
I hope it's [warfarin] keeping everything under control... Well, the stroke that I had, I don't feel sick, I don't have any pain, or anything. (P21)
B. Superior knowledge of risks and benefits
A 72-year-old male has a 30 percent chance of having a stroke regardless, but if I didn't take the Coumadin, it would be a 70 percent chance of 
having one. So I'm taking medication to avoid the stroke. (P14)
Nobody really explained to me in full what Coumadin is all about, but I did some reading about it. I know it's a blood thinner, an anti-coagulant... 
helps with the atrial fibrillation that I have, because apparently blood stays longer than it should in the atrium, and if it thickens it can go to your 
brain and you can have a stroke. (P8)
C. Patient education
Q: When you started on the Coumadin, did you receive any education about the medication?
A: Just that the doctor said to me that it's not 100 %, like anything else, but there's less chance [of stroke]. (P16)
I said to the nurses once, "Supposing I stop taking it." They said, "Oh, I wouldn't advise it, you know, because within a month, you'd have the most severe 
stroke, or it would kill you, one or the other." That scared me.(P3)
Q: Do you remember if you received any educational material about Coumadin?
A: No.
Q: Or any talk about how it works, the benefits?
A: Not that I can remember. I cannot recall that, no.
Q: Any pamphlets, any coloured paper, anything?
A: No.
Q: You don't recall?
A: If I did have, I read it, then I dismissed it... I have an appetite, I can eat and drink, I can sleep, and I still can work. Anything else, to me, is not quite 
important. It's probably wrong. I should read them and pay more attention. (P15)
Then he [physician] said, "If you go off the Coumadin for your operation, you could get a stroke. You've got a choice: you can either go off the Coumadin or 
you can stay on it and bleed to death." Not to death, he didn't say that. You'd bleed. The other way, you could have a stroke. That's all he said. So I 
presume that it could happen. (P9)
Q: Is there any sort of educational material that you would like to see on warfarin?
A: No. I've got a pile of books to read now, and as soon as I start to read, I fall asleep. The pamphlets would fare worse than the books. I don't think 
that would help. (P12)
Q: Did you have many questions about it at the time [when warfarin was initiated]?
A: No. You see, the darn trouble was that my wife would be sitting there, and I'd say, "She knows what it's all about; tell her." ... When you have a sit-
in nurse, you know, I don't worry about that stuff [getting education on the therapy]. (P3)BMC Family Practice 2004, 5:15 http://www.biomedcentral.com/1471-2296/5/15
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monly cited impacts (Table 4B). Only a small number of
participants reported experiencing significant complica-
tions related to the warfarin regime, with one case involv-
ing repeated gastro-intestinal bleeding. These patients
demonstrated a very high level of commitment towards
their warfarin management and have placed the ritual of
taking the medication at the centre of their daily routine
(Table 4C).
Patient satisfaction
The vast majority of interviewees reported a high level of
satisfaction with the care they receive from the nurses and
physicians in the clinic (Table 5A). Most participants were
also satisfied with the warfarin regime itself (Table 5B).
Only a very small number of participants expressed signif-
icant dissatisfaction. The sources of dissatisfaction, which
tended to be highly localized to specific concerns,
included the cost and inconvenience of attending the
clinic for regular INR tests, a lack of information provided
to patients, and insufficient awareness of patient history
on the part of clinic staff (Table 5C).
Discussion
The findings of this study provide significant and original
insight into the perception and experience of patients tak-
ing warfarin. The data indicate that patients tend to have
minimal input into the decision to initiate warfarin ther-
apy; many have only a superficial level of understanding
of the risks and benefits of warfarin; and the majority
retain little from the education they received regarding
warfarin therapy. This outcome is balanced, however, by
the finding that for these patients there was both a high
level of satisfaction with the care provided in the family
practice setting and a low level of impact on their day-to-
day lives.
The principal strength of this study is the insight into the
lived experience of warfarin therapy as gleaned from the
unique perspective of family practice patients currently
taking warfarin. We view this as a significant and novel
contribution to the literature as we could find no other
such study. It is important to note, however, that our sam-
ple was drawn from the patient population of an aca-
demic primary care practice that is both well-educated
and of medium-high socioeconomic status. The applica-
bility of these findings in other patient populations may
therefore be limited.
Interviewees revealed clear detachment from participation
in the decision-making process around initiating warfarin
therapy. In some cases, this detachment appeared to stem
from the particular circumstances at the time; for instance,
if the patient was involved in a medical emergency or was
admitted to hospital and had several medications initi-
ated. For others, there was a general belief or understand-
ing that warfarin is a medication without which the
Table 4: Quotations: Impact of warfarin regime
A. Minor impact
Coumadin, it's just a matter of taking the pills each day and coming for a blood test and adjusting the dose. That's all. No other impact, as far as I'm 
concerned. (P13)
I had the test [INR] done before I went to Europe. I arranged it so that two days before we flew to Europe, I had it tested, and it was 2.3, I think... 
The nurse said: "You might keep it this same way, and enjoy." And as soon as I got back, I came in and had it checked. (P15)
It's inconvenient having to come in every week, but on the other hand, I understand. (P20)
B. Moderate impact
I will only drink one glass of wine a day. I like a glass of wine. They say just go easy on the single malt, and stuff like that...There wasn't any special 
[instructions regarding diet]. We like good food, and we eat a good, balanced diet. I like seafood, and I love fish, and I like the odd steak. I try to stay 
off butter. I'm taking Becel® just now, which I don't really like, but I try to stay off the butter and cooking with all the white sauce, and butter sauce, 
and stuff like that. (P10)
I come here every 4 or 5 weeks to have the bloodwork done for Coumadin. Whenever I have this done, the nurse calls me that afternoon and says, 
"Stay on with the same milligrams" or "Change to that and that." But I feel fine [with this routine]... The only disadvantage of the Coumadin is the 
bruising and bleeding on just the slightest touch... but if that's the worst that happens, I'm not worrying about it. (P11)
I'm extremely careful with my alcohol intake, although as I said before, I'm not an everyday drinker. Other than that, the only other thing is I started 
noticing I have experienced some hair loss. (P8)
C. Major impact
Three years ago, I had two very serious stomach bleeds and I do not know, to this day, whether I should attribute it to Coumadin. Once I spent a 
couple of days in intensive care and then three months later, again a couple more days, this time in critical care. (P11)
It isn't worth it to risk a stroke by going off the Coumadin to have the hernia fixed. So Coumadin has played a major part in my life, because this 
hernia is a daily fact I have to live with... The fact that I'm taking Coumadin means that if I want to be operated on, I have to be careful... They [the 
Hernia Clinic] don't take guys like me that require a bit of time and skill and more facilities than they have. But what do guys like me do? (P14)
The thing is, the last 558 times I've taken it, which is right here [referring to the records he keeps], I went through this last night, and I found only 
three miscues the entire time I've been taking it. That works out to 0.005 percent. It's a very, very low percentage of goofing taking it. I've never 
forgotten. For at least two of these incidents, I took it at 10:00 or 10:45, instead of at 6:00. That's four hours late. I consider that a goof. Another 
time I took it in the morning instead of at night, which is a goof. (P14)BMC Family Practice 2004, 5:15 http://www.biomedcentral.com/1471-2296/5/15
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patient faced imminent risk of death – it is therefore not a
matter to be discussed or negotiated. This finding may be
a function of the age of our participants. As a group, eld-
erly patients tend to prefer a directed rather than shared
consultation. Prior research indicates that seniors are
more likely to be accepting of medical advice without
much questioning, rather than assuming a more active
role in the decision-making process [13]. This attitude was
reflected in participants' comments that "doctor know
best" and "it's the doctor's decision."
Patient knowledge of risks, benefits, and issues related to
diet and alcohol intake was low, although younger
patients demonstrated greater levels of understanding
than did those over age 75. This finding is consistent with
previous investigations. Lip and colleagues have detected
lower levels of knowledge among elderly patients; moreo-
ver, longer duration of anticoagulation does not appear to
ameliorate patient understanding significantly [14,15].
For the most part, we found that retention of instructions
pertaining to the warfarin regime was poor. Many partici-
pants reported that they simply follow the nurses' direc-
tions and have little interest in learning anything more.
The limited knowledge and seemingly low level of interest
to learn more could be attributable to the great deal of
trust invested in the expertise of the clinic staff as
discussed above. The fact that several spouses exhibited
greater understanding of the risks and benefits associated
with warfarin therapy has implications for educational
interventions recognizing the importance of the spousal
or care giver role in the monitoring of therapy.
With regard to the impact of warfarin therapy on daily life,
our results indicate that warfarin is for the most part well
tolerated and does not pose heavy additional burdens or
lifestyle changes. The majority of participants were already
taking several medications and visiting more than one
doctor on a regular basis. This sample also had a low inci-
dence of complications and previous studies have shown
that the potential for complication does not on its own
result in a significant impact [16,17]. That is, the mere
possibility of an adverse side-effect does not bring about
substantial anxiety unless the complication is actually
experienced. These results do not, however, capture the
experiences of individuals who have tried and ceased tak-
ing warfarin for whatever reasons. This population repre-
sents a high priority for future study. Additional support
may be required for individuals with multiple medical
problems. Continuity of care and a strong relationship
and identification with the primary care team that pro-
vides anticoagulation services can overcome potential
miscommunication and misunderstanding regarding side
effects and drug interaction.
The importance of the association between patient satis-
faction and adherence has been established in prior
Table 5: Quotations: Patient satisfaction
A. Satisfaction with clinic staff
Oh, I am more than pleased. I'm absolutely more than pleased. I think they're wonderful. The nurses are wonderful – you know, taking my blood, 
and phoning me, and giving me instructions. (P1)
I think they've been 100 percent. From my cardiologist to the family physician and to the pharmacists, because they're just amazing. (P10)
My doctor thought my blood was, I guess, too thick. They did an INR and recommended the Coumadin, which I didn't want to get on, because I 
knew it was warfarin and you associate that with rat poisoning. Anyway, she took the time and very patiently explained what the purpose of it was, 
and highly recommended it. I really like her. I like everybody there. They're very caring, supportive people. They're just dear. (P4)
B. Satisfaction with warfarin regime
This is a pill that keeps your blood thin, and you have to check it out [INR level]. I just do as I'm told and I'm thrilled that they keep me at 2-point-
something....I go every week, or every other week, or once a month, depending on my stability. It doesn't bother me going. (P1)
It's worked out well [the regime]. I know it has to be done, and I'm lucky in the fact that it has regulated it. It has totally regulated itself – I'm taking 
4 mg a day now. I'm only coming in once a month. (P18)
Oh, yes [happy with warfarin regime]. They let me know what the status is each week, whether it's going to level out, and whether I'm going to be 
able to stay on the same dosage and then stop going up there every week. I started going every week, and now it's been levelled to every two 
weeks. (P7)
I really couldn't say anything bad about it [warfarin regime]. Apparently I've been outstanding in how steady I would go with it, and I've been going – 
normally, for years, I've been going once a month, pretty well. A couple of times it would go up and I'd come back in two weeks, or something. (P2)
C. Sources of dissatisfaction
Nobody tells me anything. That's one of my problems with this whole bloody business. Nobody tells me how I'm doing. All I know is that I'm 
supposed to be between 2 and 3 [INR levels]. (P7)
I just more or less come when I'm ordered to. From home it's almost an hour on the bus each way, and the parking around here, the cost is wild. 
They must be financing the place with the parking. No, I would prefer not to come at all. I would prefer to forget the whole deal, but that doesn't 
seem to be in the offing at the moment. (P12)
I haven't been coming here that long, about two years I think... but I wouldn't say they're fully aware of my history and really understand the depth 
of it... Considering my history, I think they should know more. They certainly don't have my files. (P13)BMC Family Practice 2004, 5:15 http://www.biomedcentral.com/1471-2296/5/15
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research on anticoagulation. In a case-control study, Arn-
sten and colleagues [18] found that, among patients with
a regular physician, the non-adherent cases were those
who expressed dissatisfaction. In our sample, the level of
patient satisfaction was high, both with the clinic staff and
the warfarin regime itself. Based on participants' testimo-
nies, the coordination and continuity of care by a trust-
worthy team of doctors and nurses were key contributing
factors to the high satisfaction ratings. In an evaluation of
a telephone-based anticoagulation service, Waterman
found that patient satisfaction with warfarin management
was associated with the timeliness of receiving blood test
results from the service provider [19]. The high level of
patient satisfaction observed in the present study may also
be due in part to the low rate of complications (e.g., hem-
orrhage, drug interactions), which may serve to reinforce
patients' trust both in the therapy and in the health care
team.
Increasingly, theoretical models of the physician-patient
encounter advocate the inclusion of patients in the deci-
sion-making process [20]. Of course, shared decision-
making presupposes an understanding of the benefits and
risks on the part of patients. With regard to warfarin ther-
apy, patient preferences would be expected to vary accord-
ing to expected benefits or awareness of risks of suffering
a stroke. Man-Son-Hing et al have demonstrated that the
minimal clinically important difference of warfarin ther-
apy is often considerably smaller for patients than that
identified by clinicians [21]. Protheroe and colleagues, in
an observational study of patient-based decision analysis,
noted marked disagreement between patient preferences
and guideline recommendations [22]. A patient decision
aid was shown to improve knowledge and understanding
of the risks and benefits of warfarin for patients with atrial
fibrillation, and aided in therapeutic choice [23]. Given
the low level of patient knowledge observed in the present
study and elsewhere, the vision of shared decision-making
[24] remains an as yet unachieved, but laudable goal;
indeed, the present results highlight the challenges of
shared decision-making and increased autonomy in
patients with complex chronic diseases.
Conclusions
In summary, the results of this study suggest that patients
tend to have limited input into the decision to initiate
warfarin therapy. Moreover, a majority appear to lack a
comprehensive understanding of the risks and benefits
associated with treatment. These findings, however, were
balanced by the minimal impact of warfarin on daily life
and the high level of patient satisfaction. Further research
is required to assess whether these findings are similar in
other patient groups, with different demographic and
socioeconomic characteristics, including multi-cultural
communities [14]. Investigation of physician views of the
underutilization of warfarin therapy would allow for a
comparison of the patient and provider perspectives.
Clearly, there is a pressing need for innovative methods of
continuing patient education in order to communicate
the risks and benefits of warfarin therapy in a friendly,
non-threatening manner. Also, these results highlight the
tremendous influence that care providers exert on the
decision-making of patients. The development of decision
aids for anticoagulation may help patients make more
informed decisions [23,25], but only if care providers
know of their existence and take the time to use them,
assuming that such tools are feasible in a busy clinical
setting.
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